糖尿病药物发展简史。
A Brief History of the Development of Diabetes Medications.
作者信息
White John R
出版信息
Diabetes Spectr. 2014 May;27(2):82-6. doi: 10.2337/diaspect.27.2.82.
Abstract
This article provides an overview of the development of insulins, oral agents, and noninsulin injectable agents used in the management of hyperglycemia in patients with diabetes. It also briefly reviews the pharmacological impact and salient side effects of these medications.
摘要
本文概述了用于治疗糖尿病患者高血糖的胰岛素、口服药物和非胰岛素注射药物的发展情况。还简要回顾了这些药物的药理作用和主要副作用。
相似文献
1
A Brief History of the Development of Diabetes Medications.糖尿病药物发展简史。
Diabetes Spectr. 2014 May;27(2):82-6. doi: 10.2337/diaspect.27.2.82.
2
Insulins and oral hypoglycemic medications.胰岛素和口服降糖药。
Pediatr Endocrinol Rev. 2004 Nov;2 Suppl 1:153-62.
3
Pharmacotherapy for hyperglycemia in pregnancy - The new insulins.妊娠合并高血糖的药物治疗——新型胰岛素。
Diabetes Res Clin Pract. 2018 Nov;145:59-66. doi: 10.1016/j.diabres.2018.04.035. Epub 2018 May 3.
4
Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease?
Curr Opin Lipidol. 1996 Aug;7(4):227-33. doi: 10.1097/00041433-199608000-00009.
5
Pharmacologic treatment of type 2 diabetes: injectable medications.2型糖尿病的药物治疗：注射用药物
Ann Pharmacother. 2015 Jun;49(6):700-14. doi: 10.1177/1060028015573010. Epub 2015 Mar 23.
6
Insulin and oral agents for managing cystic fibrosis-related diabetes.用于治疗囊性纤维化相关糖尿病的胰岛素及口服药物。
Cochrane Database Syst Rev. 2013 Jul 26(7):CD004730. doi: 10.1002/14651858.CD004730.pub3.
7
Pharmacologic treatment of type 2 diabetes: oral medications.2型糖尿病的药物治疗：口服药物
Ann Pharmacother. 2015 May;49(5):540-56. doi: 10.1177/1060028014558289. Epub 2015 Feb 9.
8
Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.在商业管理式医疗组织中，2 型糖尿病患者对注射用抗糖尿病药物的坚持使用情况。
Curr Med Res Opin. 2010 Jan;26(1):231-8. doi: 10.1185/03007990903421994.
9
Use of Norplant in women with or at-risk for noninsulin-dependent diabetes.
J Nurse Midwifery. 1996 Jul-Aug;41(4):285-96. doi: 10.1016/0091-2182(96)00031-6.
10
Postoperative management of the diabetic patient.糖尿病患者的术后管理
Med Clin North Am. 2001 Sep;85(5):1213-28. doi: 10.1016/s0025-7125(05)70373-4.
引用本文的文献
1
Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends.沙特阿拉伯NGHA医疗保健系统中2型糖尿病药物的起始使用：当代趋势
Curr Ther Res Clin Exp. 2025 Jul 23;103:100809. doi: 10.1016/j.curtheres.2025.100809. eCollection 2025.
2
2-Hydroxyisobutyric acid targeted binding to MT-ND3 boosts mitochondrial respiratory chain homeostasis in hippocampus to rescue diabetic cognitive impairment.2-羟基异丁酸靶向结合MT-ND3可增强海马体中的线粒体呼吸链稳态，以挽救糖尿病认知障碍。
Redox Biol. 2025 Feb;79:103446. doi: 10.1016/j.redox.2024.103446. Epub 2024 Nov 28.
3
Trends in anti-diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009-2013.2009 - 2013年美国印第安人和阿拉斯加原住民中抗糖尿病药物使用、严重高血糖和严重低血糖的趋势。
Diabetes Obes Metab. 2025 Jan;27(1):328-337. doi: 10.1111/dom.16021. Epub 2024 Oct 21.
4
Evaluation of Interprofessional Delivery of Diabetes Medication Management Training Among Family Medicine Residents.评价家庭医学住院医师跨专业的糖尿病药物管理培训
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241276801. doi: 10.1177/21501319241276801.
5
Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.格列齐特和磺脲类药物在2型糖尿病当代治疗模式中的现状：一项范围综述
Diabetes Ther. 2024 Aug;15(8):1687-1716. doi: 10.1007/s13300-024-01612-8. Epub 2024 Jun 27.
6
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.估算 2 型糖尿病患者的风险因素时间路径和风险因素管理的 QALY 收益。
Pharmacoeconomics. 2024 Sep;42(9):1017-1028. doi: 10.1007/s40273-024-01398-4. Epub 2024 Jun 26.
7
Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland.瑞士法语区糖尿病患病率、知晓率、治疗率和控制率的变化趋势。
Sci Rep. 2024 Feb 28;14(1):4839. doi: 10.1038/s41598-024-54856-6.
8
Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV.药用植物抑制二肽基肽酶-IV 的药理和临床研究。
Drug Des Devel Ther. 2023 Nov 23;17:3473-3491. doi: 10.2147/DDDT.S426870. eCollection 2023.
9
Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes.开发一种患者报告结局（PRO）测量工具，以评估 2 型糖尿病患者对治疗的简单性和复杂性的感知。
J Patient Rep Outcomes. 2023 Sep 6;7(1):89. doi: 10.1186/s41687-023-00614-7.
10
Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain.高龄对西班牙真实世界中2型糖尿病合并稳定型冠状动脉疾病患者主要不良心血管事件发生率的影响
J Clin Med. 2023 Aug 10;12(16):5218. doi: 10.3390/jcm12165218.
本文引用的文献
1
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病中的疗效和安全性：一项随机临床试验的荟萃分析。
Diabetes Obes Metab. 2014 May;16(5):457-66. doi: 10.1111/dom.12244. Epub 2013 Dec 29.
2
History of current non-insulin medications for diabetes mellitus.目前糖尿病非胰岛素药物的用药史。
J Community Hosp Intern Med Perspect. 2012 Oct 15;2(3). doi: 10.3402/jchimp.v2i3.19081. Print 2012.
3
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2型糖尿病高血糖管理：以患者为中心的方法：美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的立场声明
Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19.
4
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.GLP-1 受体激动剂治疗 2 型糖尿病的安全性和耐受性：综述。
Diabetes Metab Res Rev. 2011 Sep;27(6):528-42. doi: 10.1002/dmrr.1202.
5
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂的化学差异（结构）、作用机制及药理学
J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078.
6
Thiazolidinediones: the case for early use.
Diabetes Care. 2006 Jan;29(1):154-7. doi: 10.2337/diacare.29.1.154.
7
Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome).糖尿病侏儒症（Mauriac综合征）中进行性视网膜病变且病情控制改善。
Diabetes Care. 1981 May-Jun;4(3):360-5. doi: 10.2337/diacare.4.3.360.
8
Sulfonylureas: background and development of the field.磺脲类药物：该领域的背景与发展
Diabetes Care. 1984 May-Jun;7 Suppl 1:3-7.
9
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
Diabetes Care. 1992 Feb;15(2):270-6. doi: 10.2337/diacare.15.2.270.
10
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.胰高血糖素样肽-1（7-36）酰胺对正常受试者和糖尿病患者的抗糖尿病作用。
N Engl J Med. 1992 May 14;326(20):1316-22. doi: 10.1056/NEJM199205143262003.
Zotero 插件